OBJECTIVE: Due to specific risks associated with illicit drug use, the preanaesthetic detection of illicit substances is essential. This prospective observational study evaluated oral fluid testing and self reporting of illicit drug use compared with confirmatory blood testing. METHODS: Consecutively enrolled preanaesthetic and emergency room patients (n = 939) completed a paper-based lifestyle questionnaire. An oral fluid sample was obtained and analysed for illicit substance use by a point-of-care testing device (Dräger Drugtest ® 5000). Patients who tested positive by self reporting or oral fluid testing underwent confirmatory blood testing (n = 117). RESULTS: Self reporting revealed more overall illicit substance use and more users of cannabinoids, amphetamines, opioids, cocaine and benzodiazepines than oral fluid testing. Self reporting was more sensitive than blood testing for the detection of overall illicit substance use, and for use of cannabinoids and benzodiazepines. CONCLUSIONS: Self reporting revealed higher rates of illicit substance use than oral fluid testing in preanaesthetic patients, and may lead to more interventions and more appropriately tailored treatment and anaesthesia compared with oral fluid testing.
Introduction
Illicit substance use is a worldwide problem; of the global population, 185 million people (3.1%) use illicit drugs, including infants and the elderly, and multidrug use is frequently observed. 1 Illicit substance use refers to a wide range of disorders, from occasional use to severe dependence on a substance. Coconsumption of legal substances, such as alcohol and tobacco, is widespread and complicates the perioperative management of these patients: 2 -6 70% of individuals who use illicit substances also smoke tobacco and 38% test positive for alcohol use disorder. 7 Surgical candidates who use illicit substances may benefit from brief interventions, as has been shown for alcohol use disorder 8 and smoking. 9 No studies have, however, been performed regarding brief interventions, preoperative cessation or detoxification a F Kork and R Kleinwächter contributed equally to this article.
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Patients with severe drug-use disorders are regarded as being high risk because of their complex psychiatric and physical comorbidities. Such comorbidities may include antisocial personality disorder, bipolar disorder, schizophrenia or other mood disorders, 10 as well as chronic hepatitis, HIV infection, infections involving multiresistant bacterial strains (such as methicillin-resistant Staphylococcus aureus), or endocarditis. 11 These patients require tailored anaesthetic approaches, with a lower threshold for invasive monitoring techniques, in order to avoid complications due to cannabinoid, 12, 13 cocaine, 14 amphetamine 15 or opioid 16, 17 use.
The provision of a presurgical intervention, cessation or detoxification programme, and tailored anaesthesia, depend on prior identification of the illicit substance in use. The identification of acutely intoxicated patients is straightforward, but alcohol addiction 18 and illicit substance use 7 are often underestimated by anaesthetists. Although 7.5% of surgical patients voluntarily reported use of at least one illegal substance within the previous 12 months, anaesthetists did not detect approximately 67% of these users. 7 In addition, patients may not voluntarily report their substance use.
The aim of the present study was to evaluate oral fluid testing and self reporting for the detection of illicit substance use during preanaesthetic assessment and in the emergency room.
Patients and methods

STUDY POPULATION
This prospective observational study was part of a project investigating lifestyle risk and its impact on perioperative care and emergency medicine. 7 Additionally, participation was discontinued if one of these conditions occurred before completion of the questionnaire, oral fluid or blood sampling.
The Ethics Committee of the Charité-University Medicine Berlin (EA 1/23/2004) gave advance approval for the study, and written informed consent was obtained from all participants. Subjects were approached regarding participation in the study prior to contact with a physician.
SELF REPORTING OF ILLEGAL SUBSTANCE USE
Patients were asked to complete a questionnaire regarding lifestyle risks. The questionnaire included the Alcohol Use Disorders Identification Test, 19 questions regarding illicit substance use (including 'Have you ever in your lifetime taken one of the following substances?', 'When did you last take these substances?', 'Within the last 30 days, within the last 12 months, longer 
BLOOD TESTING
Patients who were positive for illicit drug use by self reporting or oral fluid testing were eligible for confirmatory blood testing. Blood samples (6 ml taken from a peripheral arm vein) were anticoagulated with ethylenediaminetetra-acetic acid (1.8 mg/ml of blood) and immediately stored at -80°C until analysis. An analysis for 14 opioids, cocaine and two of its metabolites, five amphetamines/ecstasy drugs and 19 benzodiazepines was performed by liquid chromatography/hybrid quadrupole timeof-flight mass spectrometry (LC-QTOF-MS) using LC 1200 and MS 6530 instruments (Agilent Technologies, Waldbronn, Germany) with Agilent Masshunter Acquisition (version B.02.01) and Analysis software (version B.03.01). Chromatographic separation was performed with an RP18 column (Eclipse Plus 2.1 × 150 mm, 3.5 µm particle size; Agilent Technologies) with the following gradient elution: eluent A, 10 mM ammonium acetate in water; eluent B, 0.01% formic acid in methanol, 0 min 10%, 0 -1 min linear to 20%, 1 -6 min linear to 55%, 6 -11 min linear to 60%, 11 -13 min linear to 100%, 13 -18 min at 100%, flow rate 0.4 ml/min. After optimization, the LC-QTOF-MS instrument was applied in the product ion scan mode (known as targeted MS-MS) with the following parameters: nozzle voltage, 100 V; fragmentor voltage, 150 V (0 -10.5 min) and 190 V (10.5 -18 min); Vcap voltage, 2000 V; collision induced dissociation voltage, 6 -48 V (depending on analyte); gas temperature, 300°C; and sheath gas temperature, 400°C. For quantification, the most abundant fragment ion was generally used as the quantifier ion and the second most abundant as the qualifier ion.
Blood samples (100 µl) were mixed with 10 µl internal standard solution (1 µg/ml Nethylnordazepam in methanol) and 100 µl acetonitrile. The mixture was vortexed for 1 min and centrifuged at 16 100 g for 5 min. The supernatant was removed and 100 µl was diluted with 900 µl 10 mM ammonium acetate in water/0.01% formic acid in methanol (90/10). A 100 µl aliquot of this mixture was injected for analysis.
The system was calibrated using a fresh blood sample spiked with 43 drugs or drug metabolites at 0.5, 1, 5, 10, 50, 100, 500 or 1000 ng/ml. The resulting calibration curves were linear, with R 2 between 0.985 and 0.999. All substances were clearly detected at the lowest calibration level and the limits of quantification were between 0.5 and 1 ng/ml.
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The determination of ∆ 9 -tetrahydrocannabinol (THC), 11-hydroxy-∆ 9 -THC, 11nor-9-carboxy-∆ 9 -THC, cannabidiol and cannabinol was performed as described previously. 21 Blood testing was considered positive if any substance or metabolite was detected.
STATISTICAL ANALYSES
All statistical analyses were performed using the PASW ® statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Frequencies are reported absolutely and as percentages with corresponding 95% confidence intervals (CI). Normally distributed variables are presented as mean ± SE, and non-normally distributed variables are presented as median with quartiles. Agreement was assessed by calculating Cohen's κ with 95% CI, 22 tested for nonassociation (κ = 0), and interpreted using the categories of Landis and Koch 23 (0 < κ < 0.2, slight agreement; 0.21 < κ < 0.40, fair agreement; 0.41 < κ < 0.60, moderate agreement; 0.61 < κ < 0.80, substantial agreement; and 0.81 < 1.00, [almost] perfect agreement). In addition, positive and negative agreements were calculated. Frequencies and proportions were tested for symmetry (paired samples) using McNemar's test according to Bennett, 24 including the sensitivities and specificities (using blood testing as the gold standard). A two-tailed P-value of < 0.05 was considered to be statistically significant. Since the study was exploratory, no adjustments were made for multiple testing.
Results
In total, 1335 consecutive patients from the preanaesthetic clinic and the emergency room were asked to participate in the study. After exclusions (Fig. 1) , the data for 939 subjects were analysed. Within the study group, 127 subjects tested positive for illicit substance use by self reporting and/or oral fluid testing. Fourteen of these patients did not report illicit substance use but tested positive on oral fluid testing. All patients who tested positive on oral testing or who self reported use (within the previous 30 days) were eligible for a confirmatory blood test. Ten subjects refused or did not give a blood sample due to organizational reasons. A total of 117 blood samples were analysed (Fig. 1) . Demographic data and self reported or oral fluid testing results for illicit substance use are given in Table 1 . Blood test data for illicit substance use are shown in Table 2 .
Self reporting revealed significantly more cases of illicit substance use (P < 0.01) and more users of cannabinoids (P < 0.01), amphetamines (P = 0.04), opioids (P = 0.03), cocaine (P < 0.01) and benzodiazepines (P = 0.01) than oral fluid testing ( Table 3) .
The agreement between all drug tests for overall illicit substance use was slight (self report/oral fluid test κ = 0.13, self report/blood test κ = 0.16, oral fluid test/blood test κ = 0.07; P < 0.01). After data were subcategorized by type of illicit substance, agreement was mostly, slight to fair. Full details are shown in Table 4 .
Data regarding the sensitivity and specificity of self reporting or oral fluid testing compared with blood testing are given in Table 5 . Self reporting was significantly more sensitive but less specific than oral fluid testing for the detection of overall illicit substance use (P < 0.01 for both comparisons). In particular, self reporting was more sensitive than oral fluid testing for the detection of cannabinoids (P < 0.01) and benzodiazepines (P = 0.01), and less specific than oral fluid testing for the detection of cannabinoids (P < 0.01). Oral fluid testing was significantly more specific than self reporting for the detection of opioids and cocaine (P = 0.02 for both comparisons).
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Discussion
Oral fluid testing in the present study revealed one in 36 subjects to be recent substance users, yet one in eight subjects had voluntarily reported the use of an illicit substance within the last 30 days. Surprisingly, oral fluid testing revealed only three of the 77 self-reported users of cannabinoids, of whom 33 were confirmed by blood testing. This finding is in agreement with the results of others, who did not recommend the Dräger DrugTest ® for on-site oral fluid testing for cannabinoid use, since its accuracy was < 66% compared with liquid chromatography tandem MS. 25 A different study showed a sensitivity of 93% and specificity of 71% for a new Dräger DrugTest ® cassette that used a cut-off of 5 ng/ml instead of 25 ng/ml. 26 More patients reported the use of cannabinoids, amphetamines, opioids, cocaine or benzodiazepines than tested positive by oral fluid testing. Confirmatory blood testing detected even more users of Demographic and blood test data on illicit substance use from these German lifestyle-risk study participants who positively self reported illicit substance use or had positive oral fluid test results (n = 117) Oral fluid testing for illicit substance use opioids and benzodiazepines. This is probably due to the use of doctor-prescribed opioids or benzodiazepines, which subjects did not report as illicit substance use. The use of oral fluid testing for illicit substance use is controversial and is mainly used for forensic determination, in cases of driving under the influence of drugs (DUID). 26 -28 Correlations between blood and oral fluid drug concentrations are influenced by the pH of the oral fluid, protein binding of the substance, its pKa 29 and molecular weight, oral fluid flow rate, elimination kinetics and water solubility. 30 An international, multicentre DUID trial revealed a wide range of oral fluid : blood ratios for common substances, and concluded that the calculation of blood concentrations from oral fluid concentrations is unreliable. 28 Results were limited by lack of knowledge regarding dose, route of administration and time of last administration, as well as the unknown precise volume of the oral fluid sample. In contrast, others have found the oral fluid : blood ratio of THC to be strongly linear after controlled administration, but were unable to demonstrate a relationship 27 The present study regarded any concentration of substance above the limit of detection as illicit substance use, in contrast to oral fluid testing with the Dräger DrugTest ® 5000, which uses internal cut-offs according to the manufacturer's instructions. It is possible that this approach resulted in oversensitivity of blood testing. Between-test variations in opioid detection rates can be explained by the fact that the oral fluid test is sensitive only to opiates with a structure related to morphine and methadone, whereas blood testing also detects opioids such as tilidine, fentanyl and pethidine. 31 In a similar manner, oral fluid testing for benzodiazepines is not equally sensitive across all drugs in this group, 28 leading to a higher rate of false-negative results than blood testing. When comparing self-report results with oral fluid/blood testing, it is important to note that the detection window is between 1 and 3 days for blood or oral fluid, and the self-report questionnaire referred to the previous 30 days. Overall, self reporting of illicit substance use was more sensitive than oral fluid testing in the present study. This may lead to more interventions, and more appropriately tailored treatments and anaesthetic regimens than would be possible with oral fluid testing alone.
The 30-day prevalence rate of illicit substance use was 12.0% in the present study. This appears high in comparison with the 1- year prevalence of 7.5% reported in a larger sample by our research group. 7 Patients may have reported their substance use proactively in the present study because they were aware that oral fluid testing and blood testing were to be undertaken subsequently. The samples in the present and previous 7 studies were comparable in terms of gender, age, and alcohol and tobacco use. It is likely, therefore, that the 12.0% 30-day prevalence rate is more realistic than the 1-year prevalence rate. The apparently high 30-day prevalence of cannabinoid use detected by self reporting (8.2%) concurs with the constantly changing national 12-month prevalence rate, 32 and may be due to sampling an urban emergency room population. 33 As with any observational study, undefined factors in patient selection may result in random error. The present study conducted confirmatory blood tests only in those who tested positive by oral fluid testing or self-reported illicit substance use within the previous 30 days. Blood testing of all patients may have revealed a higher rate of illicit substance use in this population and, consequently, may have degraded the value of the self-report findings. Blood testing is generally used for confirmatory analysis in suspicious circumstances, or for forensic reasons. Screening tools must be rapid, easily accessible and cost efficient; blood testing is, therefore, not appropriate for this purpose.
In conclusion, a paper-based questionnaire administered during anaesthetic preassessment or emergency room consultations revealed a higher percentage of illicit substance use than oral fluid testing. This may lead to greater availability of treatment and intervention, and tailored anaesthesia. Due to its high specificity, oral fluid testing may be an alternative to the time-consuming gold standard blood tests for some substances.
